Abstract
The objectives of this study are to explore the clinical features and treatment outcomes and to investigate the correlation between microvessel density (MVD) and survival in patients with angioimmunoblastic T-cell lymphoma (AITL). We retrospectively analyzed clinical and follow-up data of 31 patients treated in two hospitals during 1995–2009 histologically proven AITL. We also assessed MVD in the lump of 31 previously untreated patients using α-CD34 immunohistochemical staining. The median age of the 31 patients was 48 years, eighty percent of the patients were in an advanced stage. 67.7% of them had B symptoms, with the follow-up of 2–13 years, the 5-year overall survival rate was 25.8%. The response rates (RR) of CHOP group and COP (cyclophosphamide, vincristine and prednisolone) group are 76.5 and 75%, respectively, which is no significant difference (P = 0.894). RR did not differ whether chemotherapy regimens contained anthracycline or not. The 3-year PFS rate for patients who received COP and CHOP regimen was 25.4 and 35.3% (P = 0.562), while 5-year OS rates were 25.0 and 29.4%, respectively (P = 0.667). The median PFS for patients with high MVD and low MVD were 15.1 and 30.0 months (P = 0.048), while the median OS were 20 and 45 months, respectively (P = 0.038). Patients who were sensitive to initial chemotherapy COP regimen have the similar therapeutic effect to CHOP regimen. Patients with high MVD measured in the microenvironment had worse PFS and OS than AITL patients with low expression.
Similar content being viewed by others
References
Armitage J, Vose J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–30.
Mourad N, Mounier N, Brière J, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trials. Blood. 2008;111:4463–70.
Gratzinger D, Zhao S, Tibshirani RJ, et al. Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. Lab Invest. 2008;88:38–47.
Jaffe ES, Ralfkiaer E (2001) Angioimmunobalstic T-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, et al. (eds) World health organisation classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, pp 225–226.
Gratzinger D, Zhao S, Marinelli RJ, et al. Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes. Am J Pathol1. 2007;70:1362–9.
The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma: The Non-Hodgkin’s Lymphoma Classification Project. Blood. 1997;89:3909–18.
Swerdlow SH, Campo E, Harris NL, et al. (2008) WHO Classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC, p 439.
Krenacs L, Schaerli P, Kis G, et al. Phenotype of neoplastic cells in angioimmunoblastic T-cell lymphoma is consistent with activated follicular B helper T cells. Blood. 2006;108:1110–1.
de Leval L, Rickman DS, Thielen C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T cells (TFH). Blood. 2007;109:4952–63.
Vinuesa CG, Tangye SG, Moser B, et al. Follicular B helper T cells in antibody response and autoimmunity. Nat Rev Immunol. 2005;5:853–65.
Attygalle A, Al-Jehani R, Diss TC, et al. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood. 2002;99:627–33.
Dogan A, Attygalle AD, Kyriakou C. Angioimunoblastic T-cell lymphoma. Br J Haematol. 2003;121:681–91.
Dupuis J, Boye K, Martin N, et al. Expression of CXCL13 by neoplastic cells in Angioimmunoblastic T cell-lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol. 2006;30:490–4.
Grogg KL, Attygalle AD, Macon WR, et al. Angioimmunoblastic T cell lymphoma: a neoplasm of germinal-center T-helper cells? Blood. 2005;106:1501–2.
Kim CH, Lim HW, Kim JR, et al. Unique gene expression program of human germinal center T helper cells. Blood. 2004;104:1952–60.
Yuan CM, Vergilio JA, Zhao XF, et al. CD10 and BCL6 expression in the diagnosis of angioimmunoblastic T-cell lymphoma: utility of detecting CDl0+ T -cells by flow cytometry. Hum Pathol. 2005;36:784–91.
Chtanova T, Tangye SG, Newton R, et al. T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells. J Immunol. 2004;173:68–78.
Ansel KM, Ngo VN, Hyman PL, et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature. 2000;406:309–14.
Tang XF, Li GD, Li YL, et al. Expressions of CXCL13, CD10 and bcl-6 in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified. Zhonghua Bing Li Xue Za Zhi. 2009;38:224–30.
Grogg KL, Attygalle AD, Macon WR, et al. Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified. Mod Pathol. 2006;19:1101–7.
Pautier P, Devidas A, Delmer A, et al. Angioimmunoblastic-like T-cell non Hodgkin lymphoma:outcome after chemotherapy in 33 patients and review of the literature. Leuk Lymphoma. 1999;32:545–52.
Ferreri AJ, Campo E, Ambrosetti A, et al. Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma. Ann Oncol. 2004;15:1215–21.
Vose J, Armitage J, Weisenburger D. International T-cell Lymphoma Project. International Peripheral T-cell and Natural Killer/T-Cell Lymphoma Study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–30.
Lin HN, Liu CY, Hong YC, et al. Clinical features and prognostic factors of angioimmunoblastic T-cell lymphoma in Taiwan: a single-institution experience. Leuk Lymphoma. 2010;51:2208–14.
Gallamini A, Zaja F, Patti C, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood. 2007;110:2316–23.
Joly B, Frenkel V, Gaulard P. Rituxinmab in combination with CHOP regimen in angioimmunoblastic T-cell lymphoma(AITL). Preliminary results in 9 patients treated in a single institution. Blood. 2005;106:2686.
Bruns I, Fox F, Reinecke P, et al. Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab. Leukemia. 2005;19:1993–5.
Mori M, Inoue D, Arima H, et al. Therapeutic efficacy of cyclosporin A for refractory angioimmunoblastic T cell lymphoma. Rinsho Ketsueki. 2010;51:332–8.
Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117:5827–34.
Jørgensen JM, Sørensen FB, Bendix K, et al. Expression pattern and prognostic impact of vascular endothelial growth factors VEGF and VEGF-C and their receptors Flt-1, KDR and Flt-4 in Peripheral T-cell lymhoma. Leuk Lymphoma. 2009;50:1647–60.
Ruan J, Hajjar K, Rafii S, Leonard JP. Angiogenesis and antiangiogenic therapy in non-Hodgkin’s lymphoma. Annal Oncol. 2009;20:413–24.
Kumar S, Gertz MA, Dispenzieri A, et al. Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplant. 2004;34:235–9.
Iqbal J, Weisenburger DD, Greiner TC, et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood. 2010;115:1026–36.
Acknowledgments
I confirm that the article is my original work, it has not been published elsewhere and that it has not been submitted simultaneously for publication elsewhere. I also confirm that the article is free of plagiarism, is accurate, and does not infringe on anyone’s copyright or other rights.
Author information
Authors and Affiliations
Corresponding author
Additional information
Shu Zhao and Liangyu Zhang contributed equally to the work and should be considered co-first authors.
Rights and permissions
About this article
Cite this article
Zhao, S., Zhang, L., Zhang, M. et al. Angioimmunoblastic T-cell lymphoma: the effect of initial treatment and microvascular density in 31 patients. Med Oncol 29, 2311–2316 (2012). https://doi.org/10.1007/s12032-011-0094-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12032-011-0094-7